Chronic Myeloid Leukemia

The BCR-ABL tyrosine kinase inhibitor TERN-701 has been granted an orphan drug designation from the FDA for the treatment of chronic myeloid leukemia.

The FDA has accepted Xspray Pharma's resubmitted application for Dasynoc, a potential new treatment for chronic myeloid leukemia and acute lymphoblastic leukemia.

Findings from the phase 3 ASC4FIRST trial showed that asciminib demonstrated encouraging major molecular response in patients with Philadelphia chromosome-positive chronic myeloid leukemia.

A comparison of asciminib and bosutinib demonstrated greater efficacy and safety/tolerability with asciminib for patients with chronic phase chronic myeloid leukemia.

Results from the phase 1b study of Orca-T with myeloblative chemotherapy conditioning showed the feasibility of the therapy in younger and older patients with hematologic malignancies.

A phase 1 trial of TERN-701 for chronic myeloid leukemia plans to start patient screening in December 2023, with initial data expected to be released in the second half of 2024.

During a Targeted Oncology™ Case-Based Roundtable™ event, Kendra Sweet, MD, and participants discussed dosing and toxicity concerns with tyrosine kinase inhibitors in patients with chronic-phase chronic myeloid leukemia.

According to Elisabetta Abruzzese, MD, PhD. balancing the care of the mother, the baby, as well disease burden is needed for patients with chronic myeloid leukemia who are pregnant.

There are several options the frontline setting for patients with chronic phase CML, with major randomized phase 3 trials showing long-term results for second-generation tyrosine kinase inhibitors.

In an interview with Targeted Oncology, Hagop Kantarjian, MD, analyzed the results of the phase 2, OPTIC and PACE trials and explained what these data mean for the future use and administration of ponatinib.

While tyrosine kinase inhibitors the current standard of care for most patients with CML, investigators may need to look at new options and combinations for those with TKI resistance.

Data revealed that a longer time to treatment discontinuation seen with asciminib favored its relative tolerability, correlating with the better-observed safety profile, according to data presented at the International Society for Pharmacoeconomics and Outcomes Research 2022

At the 2022 American Society for Clinical Oncology Annual Meeting, durable responses continued to be shown with asciminib compared with bosutinib in adult patients with chronic myeloid leukemia in chronic phase.

In patients with largely resistant CP-CML, ponatinib showed clinical activity when administered at the 45 mg compared with lower doses.

Two approvals for asciminib were issued by the FDA for the treatment of CML with a Ph+ mutation.

In an interview with Targeted Oncology during the SOHO Annual Meeting, Elisabetta Abruzzese, MD, provided key recommendations for managing pregnancy and chronic myeloid leukemia.

Asciminib for the treatment of 2 chronic myeloid leukemia subgroups is now under FDA consideration for approval.

The FDA granted Breakthrough Therapy Designation to the novel STAMP inhibitor asciminib for 2 populations of patients with Philadelphia chromosome-positive chronic myeloid leukemia.

The FDA has approved ponatinib for the treatment of adult patients with chronic-phase chronic myeloid leukemia with resistance or intolerance of at least 2 prior tyrosine kinase inhibitors.

MEDI2228 demonstrated promising clinical efficacy as treatment of patients with relapsed/refractory multiple myeloma with triple-refractory disease experiencing maintained responses in a phase 1 study.

Treatment with asciminib led to an almost doubling of the major molecular response rate compared with bosutinib at 24 weeks in patients with chronic-phase chronic myeloid leukemia.

High response rates and robust survival outcomes among patients with chronic-phase chronic myeloid leukemia who failed prior treatment with a second-generation tyrosine kinase inhibitor were observed in 2 clinical trials of ponatinib,.

A real-world analysis showed the positive safety and efficacy of the investigational tyrosine kinase inhibitor asciminib as treatment of patients with chronic myeloid leukemia without any alternatives in clinical practice.

Agents with novel mechanisms of action distinct from available ATP-competitive tyrosine kinase inhibitors have been tested in patients with previously treated, Philadelphia chromosome–positive chronic myeloid leukemia and offer promise to facilitate deeper remissions.

Today’s patients diagnosed with chronic myeloid leukemia can look forward to a near-normal life expectancy, provided they have good access to treatment and monitoring and are properly managed, said Jorge Cortes, MD.

During the Virtual 25th Congress of the European Hematology Association (EHA), a group of physicians described their experiences and recommendations for managing patients with myeloid malignancies during the COVID-19 pandemic and after.

Q&A With Moshe Yair Levy, MD: Weighing Risks and Benefits With the Use of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia

Chronic myeloid leukemia is a rare type of cancer, and&nbsp;tyrosine kinase inhibitors have become the standard guideline-recommended treatment for patients with <em>BCR-ABL1</em>&ndash;positive or Ph-positive CML.